ACACIA Study Is Evaluating Two Long-Acting Broadly Neutralizing Antibodies Given at HIV Treatment InitiationLOS ANGELES, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the ACACIA study (Antiretrovirals Combined with Antibodies for HIV-1 Cure in Africa), also known as A5417. ACACIA is a phase 2, double-blind, randomized study evaluating the safety and virologic and immunologic effects of the two long-acting ...